دورية أكاديمية
Harnessing natural killer cells for the treatment of ovarian cancer.
| العنوان: | Harnessing natural killer cells for the treatment of ovarian cancer. |
|---|---|
| المؤلفون: | Hoogstad-van Evert JS; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Obstetrics and Gynecology, Amphia Hospital, Breda, the Netherlands. Electronic address: Janneke.Hoogstad-vanEvert@Radboudumc.nl., Bekkers R; Department of Obstetrics and Gynecology, Catharina Ziekenhuis, Eindhoven, the Netherlands; GROW school for oncology and developmental biology, Maastricht University Medical Centre, the Netherlands., Ottevanger N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., Massuger L; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands., Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands. |
| المصدر: | Gynecologic oncology [Gynecol Oncol] 2020 Jun; Vol. 157 (3), pp. 810-816. Date of Electronic Publication: 2020 Apr 05. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, Academic Press. |
| مواضيع طبية MeSH: | Immunotherapy/*methods , Killer Cells, Natural/*transplantation , Ovarian Neoplasms/*therapy, Female ; Humans |
| مستخلص: | Introduction: Adoptive cellular immunotherapy could be an interesting new treatment option for ovarian carcinoma (OC), as research has demonstrated that OC is an immunogenic disease. In particular, natural killer (NK) cells have attracted attention due to their ability to kill tumor cells without prior sensitization. The therapeutic value of allogeneic NK cells has been first observed in hematological cancers and is increasingly being explored in solid tumors. Methods: To substantiate the rationale for NK cell therapy in OC we performed a literature search in the Pubmed database and in the international trial register clinicaltrials.gov with attention for the effect of OC on NK cell function, the effect of current treatment on NK cell biology and the evidence on the therapeutic value of NK cell therapy against OC. Results: In six clinical trials only 31 OC patients have been reported that received NK cell adoptive transfer. The majority of patients reached stable disease after NK cell therapy, with a mild pattern of side effects. In patients who received repeated infusions, more complete responses are described. All reported studies investigated the intravenous infusion of NK cells. Whereas the studies that are currently recruiting, investigate intraperitoneal infusion of allogeneic NK cells. Conclusion: In this review the pre-clinical evidence and current trials on NK cell immunotherapy in OC patients are summarized. Furthermore, challenges that have to be overcome for NK cell adoptive therapy to have a significant impact on disease outcome are discussed. Competing Interests: Declaration of competing interest The authors declare to have no conflict of interest. Research was supported by a grant from the Dutch Cancer Society KWF, grant number 2016-10100. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Immunotherapy; Natural killer cells; Ovarian cancer |
| تواريخ الأحداث: | Date Created: 20200410 Date Completed: 20210113 Latest Revision: 20210113 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.ygyno.2020.03.020 |
| PMID: | 32268953 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1095-6859 |
|---|---|
| DOI: | 10.1016/j.ygyno.2020.03.020 |